P2Y12 antagonists (Shanghai Hengrui Pharmaceuticals)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameP2Y12 antagonists (Shanghai Hengrui Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPurinergic receptor P2Y12 antagonists
TargetsPurinergic receptor P2Y12
Therapy Area/IndicationsCardiovascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Hengrui Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Hengrui Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A